Semaglutide – a long – awaited cure for obesity or an elusive treatment?
DOI:
https://doi.org/10.15584/ejcem.2024.4.3Keywords:
semaglutide, treatment, weight lossAbstract
Introduction and aim. Obesity is a challenging disease that affects various organs and cannot be easily treated. Therefore, the discovery that taking semaglutide results in weight loss caused great excitement amongst patients and medical professionals. The aim of this literature review is to explore the benefits and dangers of semaglutide and its effectiveness in treating obesity.
Material and methods. Review of articles published in PubMed since 2017 until first quarter of 2024.
Analysis of literature. Obesity is an increasing problem of the world population. There are different approaches in obesity treatment. Semaglutide seems effective in treating diabetes, as well as conditions that emerge from long-lasting obesity. It showed positive influence regarding diabetic neuropathy, cardiovascular risk and more. It is important to remember about possible adverse events. The most prominent are gastrointestinal symptoms, such as nausea, diarrhea, vomiting, and abdominal pain. New reports show complications with simultaneous use of anesthesia or coexisting depression. Larger studies on semaglutiderelated side effects will be published in 2025 and in 2026.
Conclusion. Semaglutide is an anti-diabetic drug showing promising effects in treating diabetes and in alleviating conditions caused by obesity. It is worth remembering that its side effects have not yet been fully investigated.
Downloads
References
Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obes Rev. 2019;20(6):805-815. doi: 10.1111/obr.12839
Goldenberg RM, Steen O. Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. Can J Diabetes. 2019;43(2):136-145. doi: 10.1016/j.jcjd.2018.05.008
Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008
Weghuber D, Barrett T, Barrientos-Perez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022;387(24):2245-2257. doi: 10.1056/NEJMoa2208601
Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol. 2021;12:645563. doi: 10.3389/fendo.2021.645563
Hayashi D, Edwards C, Emond JA, et al. What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients. 2023;15(22):4809. doi: 10.3390/nu15224809
The Top 300 of 2021. Clinical tools and calculators for medical professionals – ClinCalc. https://clincalc.com/DrugStats/Top300Drugs.aspx. Accessed March 1, 2024.
Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management. Cancers (Basel). 2023;15(2):485. doi: 10.3390/cancers15020485
Cooper AJ, Gupta SR, Moustafa AF, Chao AM. Sex/Gender Differences in Obesity Prevalence, Comorbidities, and Treatment. Curr Obes Rep. 2021;10(4):458-466. doi: 10.1007/s13679-021-00453-x
Obesity and overweight: WHO. World Health Organization site. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed March 8, 2024.
Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6-10. doi: 10.1016/j.metabol.2018.09.005
Novelli G, Cassadonte C, Sbraccia P, Biancolella M. Genetics: A Starting Point for the Prevention and the Treatment of Obesity. Nutrients. 2023;15(12):2782. doi: 10.3390/nu15122782
McCuen-Wurst C, Ruggieri M, Allison KC. Disordered eating and obesity: associations between binge-eating disorder, night-eating syndrome, and weight-related comorbidities. Ann N Y Acad Sci. 2018;1411(1):96-105. doi: 10.1111/nyas.13467
Styne DM, Arslanian SA, Connor EL, et al. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(3):709-757. doi: 10.1210/jc.2016-2573
Vecchié A, Dallegri F, Carbone F, et al. Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur J Intern Med. 2018;48:6-17. doi: 10.1016/j.ejim.2017.10.020
Mayoral LP, Andrade GM, Mayoral EP, et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res. 2020;151(1):11-21. doi: 10.4103/ijmr.IJMR_1768_17
Blüher M. Metabolically Healthy Obesity. Endocr Rev. 2020;41(3):bnaa004. doi: 10.1210/endrev/bnaa004
Barazzoni R, Bischoff S, Boirie Y, et al. Sarcopenic Obesity: Time to Meet the Challenge. Obes Facts. 2018;11(4):294-305. doi: 10.1159/000490361
Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019;92:82-97. doi: 10.1016/j.metabol.2018.11.014
Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab. 2021;50:101122. doi: 10.1016/j.molmet.2020.101122
Taheri H, Malek M, Ismail-Beigi F, et al. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Adv Ther. 2020;37(11):4697-4708. doi: 10.1007/s12325-020-01498-5
Rinonapoli G, Pace V, Ruggiero C, et al. Obesity and Bone: A Complex Relationship. Int J Mol Sci. 2021;22(24):13662. doi: 10.3390/ijms222413662
Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Metabolism and Metabolic Disorders and the Microbiome: The Intestinal Microbiota Associated With Obesity, Lipid Metabolism, and Metabolic Health-Pathophysiology and Therapeutic Strategies. Gastroenterology. 2021;160(2):573-599. doi: 10.1053/j.gastro.2020.10.057
Kojta I, Chacińska M, Błachnio-Zabielska A. Obesity, Bioactive Lipids, and Adipose Tissue Inflammation in Insulin Resistance. Nutrients. 2020;12(5):1305. doi: 10.3390/nu12051305
Kim MS, Kim WJ, Khera AV, et al. Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies. Eur Heart J. 2021;42(34):3388-3403. doi:10.1093/eurheartj/ehab454
Chao AM, Quigley KM, Wadden TA. Dietary interventions for obesity: clinical and mechanistic findings. J Clin Invest. 2021;131(1):e140065. doi: 10.1172/JCI140065
Gallo S, Cheskin LJ. Treatment of Obesity: Beyond the Diet. Gastroenterol Clin North Am. 2021;50(1):113-125. doi: 10.1016/j.gtc.2020.10.003
Kheniser K, Saxon DR, Kashyap SR. Long-Term Weight Loss Strategies for Obesity. J Clin Endocrinol Metab. 2021;106(7):1854-1866. doi: 10.1210/clinem/dgab091
Jabbour G, Salman A. Bariatric Surgery in Adults with Obesity: the Impact on Performance, Metabolism, and Health Indices. Obes Surg. 2021;31(4):1767-1789. doi: 10.1007/s11695-020-05182-z
Sierżantowicz R, Ładny JR, Lewko J. Quality of Life after Bariatric Surgery-A Systematic Review. Int J Environ Res Public Health. 2022;19(15):9078. doi: 10.3390/ijerph19159078
Dragano NRV, Fernø J, Diéguez C, López M, Milbank E. Recent Updates on Obesity Treatments: Available Drugs and Future Directions. Neuroscience. 2020;437:215-239. doi: 10.1016/j.neuroscience.2020.04.034
Apovian CM, Bruno CD, Kyle TK, Chow CR, Greenblatt DJ. Incomplete Data and Potential Risks of Drugs in People with Obesity. Curr Obes Rep. 2023;12(4):429-438. doi: 10.1007/s13679-023-00532-1
Moreno-Pérez O, Reyes-Garcia R, Modrego-Pardo I, et al. SEEN Diabetes Area. Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2 S-RWD). Diabetes Obes Metab. 2024;26(4):1519-1523. doi: 10.1111/dom.15431
Aroda VR, Faurby M, Lophaven S, Noone J, Wolden ML, Lingvay I. Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study. Diabetes Obes Metab. 2021;23(9):2177-2182. doi: 10.1111/dom.14453
Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22(3):442-451. doi:10.1111/dom.13955
Bonora BM, Russo G, Leonetti F, et al. GLIMPLES Study Investigators. Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study. J Endocrinol Invest. 2024;47(6):1395-1403. doi: 10.1007/s40618-024-02309-2
Yamada H, Yoshida M, Funazaki S, et al. Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings. J Cardiovasc Dev Dis. 2023;10(4):176. doi: 10.3390/jcdd10040176
Haidar L, Crane HM, Nance RM, et al. Weight loss associated with semaglutide treatment among people with HIV. AIDS. 2024;38(4):531-535. doi: 10.1097/QAD.0000000000003791
Dhanapalaratnam R, Issar T, Lee ATK, et al. Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy. Diabetologia. 2024;67(3):561-566. doi: 10.1007/s00125-023-06072-6
Magruder ML, Yao VJH, Rodriguez AN, Ng MK, Sasson V, Erez O. Does Semaglutide Use Decrease Complications and Costs Following Total Knee Arthroplasty? J Arthroplasty. 2023;38(11):2311-2315. doi: 10.1016/j.arth.2023.05.071
Magruder ML, Miskiewicz MJ, Rodriguez AN, Mont MA. Semaglutide Use Prior to Total Hip Arthroplasty Results in Fewer Postoperative Prosthetic Joint Infections and Readmissions. J Arthroplasty. 2024;39(3):716-720. doi: 10.1016/j.arth.2023.12.023
Jamal M, Alhashemi M, Dsouza C, et al. Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study. Obes Surg. 2024;34(4):1324-1332. doi: 10.1007/s11695-024-07137-0
Kanai R, Kinoshita S, Kanbe I, et al. Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes. Obes Pillars. 2024;9:100098. doi: 10.1016/j.obpill.2023.100098
Murvelashvili N, Xie L, Schellinger JN, et al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obesity (Silver Spring). 2023;31(5):1280-1289. doi: 10.1002/oby.23736
Powell-Wiley TM, Poirier P, Burke LE, et al. American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984-e1010. doi: 10.1161/CIR.0000000000000973
Mellbin LG, Bhatt DL, David JP, et al. Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials. Eur Heart J. 2024;ehae028. doi: 10.1093/eurheartj/ehae028
Kobo O, Cavender MA, Jensen TJ, Kuhlman AB, Rasmussen S, Verma S. Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis. Diabetes Obes Metab. 2024;26(3):1129-1132. doi: 10.1111/dom.15396
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi: 10.1056/NEJMoa2307563
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. doi: 10.1056/NEJMoa2306963
Xiong C, Wu J, Ma Y, et al. Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gut Microbiota in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Mice: Compared Evaluation of Liraglutide and Semaglutide Intervention. Diabetes Metab Syndr Obes. 2024;17:865-880. doi: 10.2147/DMSO.S451129
Zhang Y, Lin Y, Li G, et al. Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue. Biol Reprod. 2023;108(6):945-959. doi: 10.1093/biolre/ioad032
Carmina E, Longo RA. Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs. J Clin Med. 2023;12(18):5921. doi: 10.3390/jcm12185921
Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-522. doi: 10.1016/S2468-1253(23)00068-7
Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. doi: 10.1056/NEJMoa2028395
Flint A, Andersen G, Hockings P, et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021;54(9):1150-1161. doi: 10.1111/apt.16608
Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021; 12:645563. doi: 10.3389/fendo.2021.645563
Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang YQ. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10:996179. doi: 10.3389/fpubh.2022.996179
Gunning K. Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers. J Manag Care Spec Pharm. 2020;26(9):1077-1079. doi: 10.18553/jmcp.2020.26.9.1077
Humphrey CD, Lawrence AC. Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons. Facial Plast Surg. 2023;39(6):719-721. doi: 10.1055/a-2148-6321
Wharton S, Calanna S, Davies M et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. doi: 10.1111/dom.14551
Fujino E, Cobb KW, Schoenherr J, Gouker L, Lund E. Anesthesia Considerations for a Patient on Semaglutide and Delayed Gastric Emptying. Cureus. 2023;15(7):e42153. doi: 10.7759/cureus.42153
Queiroz VNF, Falsarella PM, de Freitas Chaves RC, Takaoka F, Socolowski LR, Garcia RG. Risk of pulmonary aspiration during semaglutide use and anesthesia in a fasting patient: a case report with tomographic evidence. Einstein (Sao Paulo). 2023;21:eRC0628. doi: 10.31744/einstein_journal/2023RC0628
Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889-897. doi: 10.1111/dom.13172
Sharma A, Parachuri N, Kumar N, et al. Semaglutide and the risk of diabetic retinopathy-current perspective. Eye (Lond). 2022;36(1):10-11. doi: 10.1038/s41433-021-01741-5
Li JR, Cao J, Wei J, Geng W. Case Report: Semaglutide-associated depression: a report of two cases. Front Psychiatry. 2023;14:1238353. doi: 10.3389/fpsyt.2023.1238353
Burruss CP, Jones JM, Burruss JB. Semaglutide-associated bullous pemphigoid. JAAD Case Rep. 2021;15:107-109. doi: 10.1016/j.jdcr.2021.07.027
Billings SA, Felix HM, Prier CC, Hedges MS. Rhabdomyolysis Associated With Semaglutide Therapy: A Case Report. Cureus. 2023;15(12):e50227. doi: 10.7759/cureus.50227
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
